葡萄糖-6-磷酸脱氢酶缺乏的急性冠状动脉综合征患者在接受经皮冠状动脉介入治疗时阿司匹林的安全性。
Aspirin safety in glucose-6-phosphate dehydrogenase deficiency patients with acute coronary syndrome undergoing percutaneous coronary intervention.
作者信息
Feghaly Julien, Al Hout Abdul Rahman, Mercieca Balbi Mattew
机构信息
St George's, University of London, London, UK.
Department of Cardiology, Mater Dei Hospital, Msida, Malta.
出版信息
BMJ Case Rep. 2017 Oct 9;2017:bcr-2017-220483. doi: 10.1136/bcr-2017-220483.
Abstract
The use of aspirin, as part of a dual antiplatelet therapy regimen, is an established standard following coronary stenting in patients suffering from acute coronary syndrome (ACS). However, in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, precaution is always taken with aspirin use, due to the risk of haemolysis. We reviewed all previous cases of G6PD deficient patients with ACS, in addition to a review of the available literature, to better understand the safety of aspirin use in this population. To date, there are no reported cases of haemolysis following aspirin use in this patient group and no guideline is established to date.
摘要
作为双联抗血小板治疗方案的一部分，使用阿司匹林是急性冠状动脉综合征（ACS）患者冠状动脉支架置入术后的既定标准。然而，在葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的患者中，由于存在溶血风险，使用阿司匹林时总是要谨慎。我们回顾了既往所有G6PD缺乏的ACS患者病例，并查阅了现有文献，以更好地了解该人群使用阿司匹林的安全性。迄今为止，尚无该患者群体使用阿司匹林后发生溶血的报告病例，且目前尚未制定相关指南。
相似文献
1
Aspirin safety in glucose-6-phosphate dehydrogenase deficiency patients with acute coronary syndrome undergoing percutaneous coronary intervention.葡萄糖-6-磷酸脱氢酶缺乏的急性冠状动脉综合征患者在接受经皮冠状动脉介入治疗时阿司匹林的安全性。
BMJ Case Rep. 2017 Oct 9;2017:bcr-2017-220483. doi: 10.1136/bcr-2017-220483.
2
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症与急性冠状动脉综合征患者的抗血小板和侵入性治疗。阿司匹林的安全性。
J Clin Pharm Ther. 2015 Jun;40(3):349-52. doi: 10.1111/jcpt.12262. Epub 2015 Mar 25.
3
Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists.葡萄糖-6-磷酸脱氢酶缺乏症患者经皮冠状动脉介入治疗后的抗血小板治疗：临床和介入心脏病学家的重新评估
Cardiovasc Revasc Med. 2017 Apr-May;18(3):226-229. doi: 10.1016/j.carrev.2016.11.011. Epub 2016 Nov 28.
4
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.急性冠状动脉综合征患者经皮冠状动脉介入治疗后6个月双联抗血小板治疗的安全性：智能血管成形术研究团队-急性冠状动脉综合征患者经皮冠状动脉介入治疗后6个月双联抗血小板治疗的安全性（SMART-DATE）前瞻性多中心随机试验的原理与设计
Am Heart J. 2016 Dec;182:1-8. doi: 10.1016/j.ahj.2016.07.022. Epub 2016 Aug 26.
5
Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.经皮冠状动脉介入治疗患者阿司匹林不耐受的管理。单药抗血小板治疗的作用：一项回顾性多中心研究。
Minerva Cardioangiol. 2019 Apr;67(2):94-101. doi: 10.23736/S0026-4725.19.04787-X. Epub 2019 Mar 18.
6
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.替格瑞洛与替罗非班在接受经皮冠状动脉介入治疗的非ST段抬高型急性冠状动脉综合征患者中的抗血小板作用。TE-CLOT试验结果。
Thromb Haemost. 2016 Jan;115(1):213-21. doi: 10.1160/TH15-02-0180. Epub 2015 Nov 19.
7
Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.急性冠状动脉综合征冠状动脉支架置入术后优化双联抗血小板治疗的策略
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):347-355. doi: 10.1177/1074248416683048. Epub 2016 Dec 21.
8
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.一项开放性、2×2 析因、随机对照临床试验，旨在评估在伴有心房颤动、急性冠状动脉综合征和/或经皮冠状动脉介入治疗的患者中，与维生素 K 拮抗剂相比，使用阿哌沙班的安全性，以及与安慰剂相比，使用阿司匹林的安全性：AUGUSTUS 试验的原理和设计。
Am Heart J. 2018 Jun;200:17-23. doi: 10.1016/j.ahj.2018.03.001. Epub 2018 Mar 9.
9
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).根据氯吡格雷和阿司匹林血小板反应性评估冠状动脉支架置入术后的血栓形成和出血事件：VerifyNow法国注册研究（VERIFRENCHY）
Arch Cardiovasc Dis. 2014 Apr;107(4):225-35. doi: 10.1016/j.acvd.2014.03.004. Epub 2014 Apr 29.
10
Impact of glucose-6-phosphate dehydrogenase deficiency on the severity of coronary atherosclerosis in patients with acute coronary syndromes.葡萄糖-6-磷酸脱氢酶缺乏对急性冠脉综合征患者冠状动脉粥样硬化严重程度的影响。
J Cardiovasc Med (Hagerstown). 2021 Nov 1;22(11):813-817. doi: 10.2459/JCM.0000000000001227.
引用本文的文献
1
Late-onset aspirin-related hemolysis and subsequent subdural hemorrhage in patient with glucose-6-phosphate dehydrogenase deficiency.葡萄糖-6-磷酸脱氢酶缺乏症患者迟发性阿司匹林相关溶血及随后的硬膜下出血
Clin Case Rep. 2024 Jan 30;12(2):e8450. doi: 10.1002/ccr3.8450. eCollection 2024 Feb.
2
Molecular characterization of G6PD mutations identifies new mutations and a high frequency of intronic variants in Thai females.对 G6PD 基因突变的分子特征分析确定了泰国女性中的新突变和大量内含子变异。
PLoS One. 2023 Nov 15;18(11):e0294200. doi: 10.1371/journal.pone.0294200. eCollection 2023.
3
Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review.遗传性碳水化合物代谢紊乱相关的代谢性心肌病和心脏缺陷：系统综述。
Int J Mol Sci. 2023 May 11;24(10):8632. doi: 10.3390/ijms24108632.
4
Association between aspirin-induced hemoglobin decline and outcome after acute ischemic stroke in G6PD-deficient patients.葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症患者急性缺血性脑卒中后阿司匹林诱导的血红蛋白下降与结局的关系。
CNS Neurosci Ther. 2021 Oct;27(10):1206-1213. doi: 10.1111/cns.13711. Epub 2021 Aug 8.
5
Resistance to Acetylsalicylic Acid in Patients with Coronary Heart Disease Is the Result of Metabolic Activity of Platelets.冠心病患者对乙酰水杨酸的抵抗是血小板代谢活动的结果。
Pharmaceuticals (Basel). 2020 Aug 1;13(8):178. doi: 10.3390/ph13080178.
6
Role of PFO Closure in Ischemic Stroke Prevention.卵圆孔未闭封堵术在缺血性卒中预防中的作用。
Curr Treat Options Cardiovasc Med. 2019 Nov 14;21(11):63. doi: 10.1007/s11936-019-0775-7.
本文引用的文献
1
Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists.葡萄糖-6-磷酸脱氢酶缺乏症患者经皮冠状动脉介入治疗后的抗血小板治疗：临床和介入心脏病学家的重新评估
Cardiovasc Revasc Med. 2017 Apr-May;18(3):226-229. doi: 10.1016/j.carrev.2016.11.011. Epub 2016 Nov 28.
2
Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents.第二代药物洗脱支架治疗患者双联抗血小板治疗持续时间的Meta分析
Am J Cardiol. 2016 Jun 1;117(11):1714-23. doi: 10.1016/j.amjcard.2016.03.005. Epub 2016 Mar 19.
3
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.高出血风险患者的无聚合物涂层药物洗脱冠状动脉支架。
N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14.
4
Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents.葡萄糖-6-磷酸脱氢酶缺乏症患者接受药物洗脱支架PCI时的双联抗血小板治疗
J Atheroscler Thromb. 2015;22(5):535-41. doi: 10.5551/jat.29371. Epub 2015 Apr 3.
5
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症与急性冠状动脉综合征患者的抗血小板和侵入性治疗。阿司匹林的安全性。
J Clin Pharm Ther. 2015 Jun;40(3):349-52. doi: 10.1111/jcpt.12262. Epub 2015 Mar 25.
6
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.第二代药物洗脱支架置入后 6 个月与 12 个月双联抗血小板治疗：SECURITY 随机临床试验。
J Am Coll Cardiol. 2014;64(20):2086-97. doi: 10.1016/j.jacc.2014.09.008. Epub 2014 Sep 15.
7
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).2014 欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）心肌血运重建特别工作组。由欧洲经皮心血管介入协会（EAPCI）提供特别贡献制定。
Eur J Cardiothorac Surg. 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366. Epub 2014 Aug 29.
8
Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction [corrected].第二代药物洗脱支架与裸金属支架治疗 ST 段抬高型心肌梗死的支架血栓形成：直接经皮冠状动脉介入治疗临床试验的网络荟萃分析 [更正]。
Circ Cardiovasc Interv. 2014 Feb;7(1):49-61. doi: 10.1161/CIRCINTERVENTIONS.113.000412. Epub 2013 Nov 26.
9
Dual anti-platelet therapy in patients with G6PD deficiency after percutaneous coronary intervention.
Int J Cardiol. 2013 May 10;165(2):380-2. doi: 10.1016/j.ijcard.2012.08.024. Epub 2012 Sep 11.
10
Glucose-6-phosphate dehydrogenase (G6PDH) deficiency in a patient with ST-segment elevation acute myocardial infarction successfully treated by simple thrombectomy.葡萄糖-6-磷酸脱氢酶（G6PDH）缺乏症患者行单纯血栓切除术成功治疗 ST 段抬高型急性心肌梗死。
J Atheroscler Thromb. 2011;18(5):425-30. doi: 10.5551/jat.6858. Epub 2011 Feb 5.
Zotero 插件